Cancer immunotherapy company CEL-SCI Corporation (NYSE American:CVM) said on Tuesday that the underwriters have announced the full exercise of 90,959 additional shares of common stock in over-allotment option in connection with its underwritten public offering.
The company had issued 606,395m shares of its common stock under its prior underwritten public offering.
Following the full exercise of the underwriters' over-allotment option, the company raised total gross proceeds from the offering of USD6.325m.
Aegis Capital Corp acted as the sole book-running manager for the offering.
CEL-SCI's lead investigational therapy Multikine is currently in a pivotal Phase 3 clinical trial involving head and neck cancer, for which the company has received Orphan Drug Status from the FDA.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval